💊 Verifica DM Tablet
Verifica DM Tablet is a prescription medicine used for the management of Type 2 Diabetes Mellitus (T2DM). It combines Dapagliflozin 10mg, Vildagliptin 100mg, and Metformin Hydrochloride 500mg, offering three complementary mechanisms to improve blood glucose control. It is recommended along with a balanced diet, regular exercise, and lifestyle modifications.
- Dapagliflozin (SGLT2 inhibitor) removes excess glucose through urine.
- Vildagliptin (DPP-4 inhibitor) increases insulin release when blood sugar is high and reduces glucagon secretion.
- Metformin (Biguanide) decreases glucose production in the liver and improves insulin sensitivity.
Together, these medicines help lower fasting and post-meal blood sugar levels and support long-term diabetes management.
⭐ Key Benefits
- Helps control Type 2 Diabetes
- Triple-action blood sugar management
- Improves insulin sensitivity
- Reduces fasting and post-meal glucose levels
- Supports HbA1c reduction
- Helps lower the risk of diabetes-related complications when used as prescribed
⚙️ How It Works
- Dapagliflozin removes excess glucose through urine.
- Vildagliptin improves the body's insulin response after meals.
- Metformin decreases glucose production by the liver and improves insulin sensitivity.
💊 Usage Instructions
- Take only as prescribed by your doctor.
- Preferably take with food to reduce stomach upset.
- Swallow the tablet whole with water.
- Take at the same time every day.
- Continue diet, exercise, and regular blood sugar monitoring during treatment.
⚠️ Safety Information
- Prescription medicine – use only under medical supervision
- Monitor blood glucose and kidney function regularly.
- Drink adequate fluids to reduce the risk of dehydration.
- Inform your doctor if you have kidney disease, liver disease, heart disease, or recurrent urinary tract infections.
- Common side effects include increased urination, urinary or genital infections, nausea, diarrhoea, dizziness, and low blood sugar (especially with other antidiabetic medicines).
